310 related articles for article (PubMed ID: 35645559)
1. Association between Inhaled β
Amegadzie JE; Gamble JM; Farrell J; Gao Z
Int J Chron Obstruct Pulmon Dis; 2022; 17():1205-1217. PubMed ID: 35645559
[TBL] [Abstract][Full Text] [Related]
2. Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists.
Rebordosa C; Plana E; Rubino A; Aguado J; Martinez D; Lei A; Daoud S; Saigi-Morgui N; Perez-Gutthann S; Rivero-Ferrer E
Int J Chron Obstruct Pulmon Dis; 2022; 17():1715-1733. PubMed ID: 35941901
[TBL] [Abstract][Full Text] [Related]
3. Gender Differences in Inhaled Pharmacotherapy Utilization in Patients with Obstructive Airway Diseases (OADs): A Population-Based Study.
Amegadzie JE; Gamble JM; Farrell J; Gao Z
Int J Chron Obstruct Pulmon Dis; 2020; 15():2355-2366. PubMed ID: 33061353
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
Suissa S; Dell'Aniello S; Ernst P
Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
[TBL] [Abstract][Full Text] [Related]
5. Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework.
Chen CY; Pan SW; Hsu CC; Liu JJ; Kumamaru H; Dong YH
Respir Res; 2023 Sep; 24(1):239. PubMed ID: 37775734
[TBL] [Abstract][Full Text] [Related]
6. Risk of all-cause mortality or hospitalization for pneumonia associated with inhaled β2-agonists in patients with asthma, COPD or asthma-COPD overlap.
Amegadzie JE; Gamble JM; Farrell J; Gao Z
Respir Res; 2022 Dec; 23(1):364. PubMed ID: 36539784
[TBL] [Abstract][Full Text] [Related]
7. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.
Yang M; Li Y; Jiang Y; Guo S; He JQ; Sin DD
Eur Respir J; 2023 Feb; 61(2):. PubMed ID: 36137586
[TBL] [Abstract][Full Text] [Related]
10. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada.
Tavakoli H; Johnson KM; FitzGerald JM; Sin DD; Gershon AS; Kendzerska T; Sadatsafavi M
Int J Chron Obstruct Pulmon Dis; 2019; 14():2003-2013. PubMed ID: 31564848
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
Suissa S; Dell'Aniello S; Ernst P
Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
[TBL] [Abstract][Full Text] [Related]
12. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
[TBL] [Abstract][Full Text] [Related]
13. Comparative safety and effectiveness of inhaled bronchodilators and corticosteroids for treating asthma-COPD overlap: a systematic review and meta-analysis.
Amegadzie JE; Gorgui J; Acheampong L; Gamble JM; Farrell J; Gao Z
J Asthma; 2021 Mar; 58(3):344-359. PubMed ID: 31668101
[TBL] [Abstract][Full Text] [Related]
14. A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink.
Rebordosa C; Plana E; Rubino A; Aguado J; Lei A; Daoud S; Saigi-Morgui N; Perez-Gutthann S; Rivero-Ferrer E
Int J Chron Obstruct Pulmon Dis; 2021; 16():1461-1475. PubMed ID: 34103906
[TBL] [Abstract][Full Text] [Related]
15. A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease.
D'Urzo A; Donohue JF; Kardos P; Miravitlles M; Price D
Expert Opin Pharmacother; 2015; 16(12):1845-60. PubMed ID: 26194213
[TBL] [Abstract][Full Text] [Related]
16. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.
Wang MT; Liou JT; Lin CW; Tsai CL; Wang YH; Hsu YJ; Lai JH
JAMA Intern Med; 2018 Feb; 178(2):229-238. PubMed ID: 29297057
[TBL] [Abstract][Full Text] [Related]
17. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
[TBL] [Abstract][Full Text] [Related]
18. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
19. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice.
Suissa S; Dell'Aniello S; Ernst P
Chest; 2019 Jun; 155(6):1158-1165. PubMed ID: 30922950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
